Urogen Pharma Ltd (URGN) Inventory Turnover Ratio, from third quarter 2026 to third quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Urogen Pharma Ltd   (NASDAQ: URGN)
 

Urogen Pharma Ltd Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Due to inventory build up in the third quarter 2026, Urogen Pharma Ltd 's inventory turnover ratio sequentially decreased to 1.3 in the third quarter 2026, unsurprisingly, as the Urogen Pharma Ltd markets continue to deteriorate, and URGN's faces growing challenges to bring down its inventories. Urogen Pharma Ltd 's average inventory processing period in the Sep 30 2026 quarter, has increased to 281 days, from 237 days, in the Jun 30 2026 quarter.

Within Healthcare sector 257 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 1257 in the second quarter 2026, to 1443.

URGN Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Urogen Pharma Ltd Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

URGN Inventory Turnover Ratio (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Inventory Growth 602.12 % 545.89 % 216.48 % 19.9 % 22.17 %
Y / Y Cost of Sales Growth 128.86 % 85.13 % 77.64 % 33.1 % 33.63 %
Inventory Turnover Ratio (TTM) 1.3 1.54 2.38 3.05 3.01
URGN's Total Ranking # 1443 # 1257 # 1420 # 1101 #
Average inventory processing period 281 236 153 120 121
Seq. Inventory Growth 2.28 % 120.35 % 105.81 % 51.37 % -5.91 %
Seq. Cost of Sales Growth 14.15 % 58.78 % 25.84 % 0.34 % -7.66 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 69
Healthcare Sector # 258
Overall Market # 1443

Inventory Turnover Ratio Statistics
High Average Low
4.25 3.13 1.54
(Sep 30 2023)   (Jun 30 2026)



URGN Company Profile >> Back to URGN Efficiency Comparisons >> Compare URGN Inventory Turnover Ratio to its Competitors

Financial Statements
Urogen Pharma Ltd 's Inventories $ 25 Millions Visit URGN's Balance sheet
Urogen Pharma Ltd 's Cost of Revenues TTM $ 22 Millions Visit URGN's Income Statement
What are URGN's Sales? Visit URGN's Sales by Segment

Other Inventory Turnover Ratios
Urogen Pharma Ltd 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
URGN's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for URGN's Competitors
Inventory Turnover Ratio for URGN's Suppliers
Inventory Turnover Ratio for URGN's Customers

You may also want to know
URGN's Sales Growth Rates URGN's Pe Price to earnings ratio URGN's Receivables Turnover Ratio URGN's Stock Quote
URGN's Net Income Growth Rates URGN's Ps Price to Sales ratio URGN's Sales per Employee URGN's Asset Turnover Ratio
URGN's Net Margin URGN's Pb Price to Book ratio URGN's Financial Strength Ratios URGN's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Sep 30 2026 Inventories at quarter ending Sep 30 2026
Mirum Pharmaceuticals Inc   2.35 $ 59.684  Millions$ 25  Millions
Aquestive Therapeutics Inc   2.34 $ 16.928  Millions$ 7  Millions
Resmed Inc   2.33 $ 2,214.675  Millions$ 952  Millions
Beta Bionics Inc   2.31 $ 53.285  Millions$ 23  Millions
Merit Medical Systems Inc  2.25 $ 817.001  Millions$ 363  Millions
Rigel Pharmaceuticals Inc  2.24 $ 29.869  Millions$ 13  Millions
Bioventus Inc   2.24 $ 183.856  Millions$ 82  Millions
Johnson and Johnson  2.17 $ 32,222.000  Millions$ 14,824  Millions
Standard Biotools Inc   2.16 $ 39.539  Millions$ 18  Millions
Icu Medical Inc  2.14 $ 1,304.538  Millions$ 609  Millions
Glaukos Corp  2.13 $ 131.180  Millions$ 62  Millions
Halozyme Therapeutics Inc   2.13 $ 319.654  Millions$ 150  Millions
Organon and Co   2.08 $ 2,859.000  Millions$ 1,371  Millions
Repligen Corp  2.07 $ 372.472  Millions$ 180  Millions
Boston Scientific Corporation  2.06 $ 6,502.000  Millions$ 3,153  Millions
Bausch and Lomb Corp  2.01 $ 1,986.000  Millions$ 990  Millions
Clearpoint Neuro Inc   1.98 $ 17.564  Millions$ 9  Millions
Intuitive Surgical Inc   1.91 $ 3,799.300  Millions$ 1,986  Millions
Indivior Pharmaceuticals Inc   1.88 $ 208.000  Millions$ 111  Millions
Tenet Healthcare Corp  1.88 $ 642.000  Millions$ 342  Millions
Haemonetics Corporation  1.80 $ 558.423  Millions$ 310  Millions
Iradimed Corporation  1.78 $ 21.878  Millions$ 12  Millions
Ceribell Inc   1.74 $ 12.160  Millions$ 7  Millions
Axsome Therapeutics Inc   1.67 $ 58.422  Millions$ 35  Millions
Insmed Inc  1.66 $ 237.067  Millions$ 143  Millions
Stryker Corp  1.66 $ 9,116.000  Millions$ 5,499  Millions
Bruker Corporation  1.66 $ 1,838.200  Millions$ 1,110  Millions
Bio rad Laboratories Inc   1.64 $ 1,264.000  Millions$ 769  Millions
Pfizer Inc  1.64 $ 16,940.000  Millions$ 10,322  Millions
Integra Lifesciences Holdings Corp  1.62 $ 789.329  Millions$ 486  Millions

Date modified: 2026-11-07T13:22:54+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.